Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus.

Détails

ID Serval
serval:BIB_178CB13DB61C
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus.
Périodique
Rheumatology
Auteur(s)
Pröbstel A.K., Thanei M., Erni B., Lecourt A.C., Branco L., André R., Roux-Lombard P., Koenig K.F., Huynh-Do U., Ribi C., Chizzolini C., Kappos L., Trendelenburg M., Derfuss T.
Collaborateur(s)
Swiss Systemic Lupus Erythematosus Cohort Study Group
ISSN
1462-0332 (Electronic)
ISSN-L
1462-0324
Statut éditorial
Publié
Date de publication
01/05/2019
Peer-reviewed
Oui
Volume
58
Numéro
5
Pages
908-913
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
To determine frequency and syndrome specificity of novel and known nervous system (NS)-directed antibodies in a large, unbiased cohort of SLE patients in the Swiss SLE Cohort Study.
This retrospective pilot study included 174 patients in a cross-sectional and 102 in a longitudinal study. Antibodies against 12 NS antigens [myelin oligodendrocyte glycoprotein (MOG), neurofascin 186 (NF186), aquaporin-4 (AQP4), N-methyl-D-aspartate receptor (subunit NR1) (NMDAR-NR1), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (subunits 1 and 2) (AMPAR1/2), gamma-aminobutyric acid B receptor (subunits B1 and B2) (GABABR1/2), glutamate decarboxylase 65 (GAD65), glycine receptor (GlyR), contactin-associated protein-like 2 (CASPR2), leucine-rich glioma-inactivated 1 (LGI1), metabotropic glutamate receptor 5 (mGluR5) and dipeptidyl-peptidase-like protein 6 (DPPX)] were screened with validated cell-based assays and correlated with clinical and diagnostic findings.
Twenty-three of one hundred and seventy-four (13.2%) patients harboured antibodies against MOG (n = 14), NF186 (n = 6), GAD65 (n = 2), AQP4 and GlyR (n = 1). Anti-MOG antibodies were most frequently found in the cohort (8%). Thirteen of the anti-NS antibody-positive patients showed clinical symptoms of NS involvement, a subgroup of which (n = 8) resembled the syndrome associated with the antibody. Nine patients harboured antibodies without neurological symptoms and one patient was lost to follow-up. The frequency of NPSLE was significantly higher in the anti-NS antibody-positive patients (13/23, 56.5%: MOG 6/14, 42.9%; NF186 5/6, 83.3%; GAD65 2/2, 100%; AQP4/GlyR 0/1, 0%) compared with the antibody-negative cohort (21/151, 13.9%) (chi-square test, P < 0.0001).
Anti-NS antibodies, most prevalently anti-MOG antibodies, are significantly associated with NPSLE and manifest with the distinct neurological syndrome associated with the antibody in a subgroup. Follow-up studies in large, independent cohorts will reveal whether these anti-NS antibodies could serve as a diagnostic and prognostic biomarker for NPSLE and enable tailored treatment decisions in this challenging and diverse patient cohort.
Mots-clé
B cells, anti-MOG antibodies, autoantibodies, biomarker, inflammation, nervous system involvement, neuropsychiatric systemic lupus erythematosus, systemic lupus erythematosus
Pubmed
Web of science
Création de la notice
04/11/2018 16:19
Dernière modification de la notice
20/12/2019 6:21
Données d'usage